IC14 SSTI Flashcards

1
Q

How do SSTIs come about? (Pathogenesis)

A

Disruption of normal host cell defenses (eg. skin break) –> allows overgrowth & invasion of skin and soft tissue by pathogenic microorganisms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the risk factors for SSTIs?

A
  1. disruption of skin barrier
    - traumatic causes (lesions, abrasions, burns, surgery, bites from humans/animals/insects, IV drug use)
    - nontraumatic causes (ulcers, tinea pedis, dermatitis, chemical irritants)
    - impaired venous & lymphatic drainage
    - peripheral artery disease
  2. conditions that predispose to infection
    - DM, cirrhosis, neutropenia, HIV, transplant, immunosuppression
  3. history of cellulitis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How do you prevent SSTIs?

A
  1. management of risk factors
  2. good wound care
  3. treat tinea pedis
  4. prevent dry, cracked skin
  5. good foot care for DM patients to prevent wounds & ulcers
  6. removal of foreign objects, irrigation, tissue debridement
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How do you diagnose a SSTI?

A

physical exam & patient history

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Where should you and should you NOT take samples for cultures for SSTIs from?

A

do NOT take cultures from:
- open, draining wounds (v likely contaminated)
- wound swabs

take cultures from:
- deep in the wound after surface cleansed
- base of closed abscess
- curettage > wound swab/irrigation (debridement of top layers before taking tissue sample)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Do you need to take blood samples for SSTIs?

A

Only for severe SSTI or immunocompromised patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe impetigo

A

erythematous papules that develop into vesicles and pustules that rupture, with the dried discharge forming a honey-colored crust on a erythematous base

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe ecthyma

A

ulcerative form of impetigo that occurs in deeper skin layers (not a progression of impetigo; they are diff SSTIs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe furuncles and carbuncles

A

furuncle (boil) - infection of hair follicle
carbuncle - group of furuncles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe skin abscesses

A

collection of pus within dermis and deeper skin tissue; painful, tender and red nodules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe erysipelas

A

fiery red painful plaque (raised above surrounding skin) with well-demarcated edges; common on face and lower extremities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe cellulitis

A

involves deeper and subq fats; acute, diffuse, spreading, non-elevated, poorly demarcated area of erythema, mostly unilateral (on one limb); typically in lower extremities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the likely pathogens for each SSTI?

A
  • impetigo: Staph, strep pyogenes
  • ecthyma: Strep pyogenes (GAS)
  • nonpurulent (cellulitis, erysipelas): Strep pyogenes
  • purulent (purulent cellulitis, furuncles, carbuncles, skin abscesses): Staph aureus, Strep pyogenes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the two kinds of MRSA that can cause SSTIs?

A

community-acquired MRSA
healthcare-associated MRSA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How are the two MRSAs different?

A

CA-MRSA and HA-MRSA are genetically different
1. PVL (Panton-Valentine leucocidin) [cytotoxin]
2. SCCmec (CA: IV, HA: II) [mobile genetic element for novel specific PBP2a]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the prevalence of the two MRSAs involved in SSTIs

A

CA-MRSA: More common in USA
HA-MRSA: Usually almost always HA-MRSA in SG, so have to treat as long as patient has MRSA risk factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Define HA-MRSA

A

patient develops MRSA infection within
1. 2 days of being in hospital
2. 12 months of being discharged from hospital

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the risk factors for HA-MRSA?

A
  • antibiotic use
  • recent hospitalization/surgery (for a decent duration; doesn’t count if just visiting etc)
  • prolonged hospitalization
  • ICU
  • hemodialysis
  • MRSA colonization
  • close proximity to MRSA colonized/infected people
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Describe the treatment for mild impetigo (limited lesions)

A

Likely pathogen: Staph (MSSA), strep

THEORY: Topical mupirocin BD x 5/7
NOT recommended; reserved for MRSA decolonization in hospitals

IN PRACTICE: no need to treat as self-limiting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Describe the EMPIRIC treatment for impetigo/ecthyma (multiple lesions)

A

Likely pathogens:
impetigo: Staph (MSSA), strep
ecthyma: grp A strep

  1. PO beta lactams
    - Cloxacillin
    - Cephalexin
  2. PO Clindamycin (penicillin allergy)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Describe the CULTURE-DIRECTED treatment for impetigo/ecthyma (multiple lesions) if it is caused by
1. Strep pyogenes (Grp A strep)
2. MSSA

A

Strep pyogenes:
1. PO penicillins
- Pen V
- Amoxicillin

MSSA:
1. PO beta lactams
- Cloxacillin
- Cephalexin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the typical treatment duration of impetigo & ecthyma for
1. mild infection
2. moderate to severe infection

A
  1. 5-7 days
  2. moderate to severe: 10-14 days
23
Q

What is the main treatment for purulent SSTIs (purulent cellulitis, furuncles, carbuncles, skin abscesses)?

A

incision & drainage (source control)

24
Q

When do we use antibiotics for purulent SSTIs?

A
  1. unable to drain completely
  2. lack of response to I&D
  3. extensive disease involving many sites
  4. extreme ages (v young/old)
  5. immunosuppressed
  6. signs of systemic illness (2/4 of SIRS criteria)
  7. IV abx for severe disease state
25
Describe the SIRS criteria
SIRS = systemic inflammatory response syndrome 1. temp (>38 or <36) 2. WBC (>12 or <4) 3. HR (>90) 4. RR (>24)
26
Describe the treatment to be given for purulent SSTIs that are 1. mild 2. moderate 3. severe
Likely pathogens: Staph aureus (MSSA) 1. I&D + warm compress 2. I&D + PO abx - Cloxacillin - Cephalexin - Clindamycin (Penicillin allergy) 3. I&D + IV abx - Cloxacillin - Cefazolin - Clindamycin - Vanco
27
Describe the empiric treatment to be given for purulent SSTIs that involve MRSA
PO - co-trimoxazole - doxycyline - clindamycin IV - vanco - daptomycin - linezolid (daptomycin & linezolid reserved for VRE/vanco allergy)
28
What happens if purulent SSTI occurs near perioral/perirectal/ vulvovaginal areas?
add G(-) anaerobic coverage
29
Describe the empiric treatment to be given for purulent SSTIs that involve G(-) anaerobes
amoxicillin-clavulanate (Augmentin) pip-tazo (if risk of resistant strain) carbapenem (if super duper sick)
30
What is the typical treatment duration for purulent SSTIs?
5-10 days
31
Describe the treatment to be given for nonpurulent SSTIs that are 1. mild 2. moderate 3. severe
Likely pathogen: Grp A strep 1. PO abx - Pen V - Amoxicillin - Cloxacillin - Cephalexin - Clindamycin (penicillin allergy) 2. moderate = signs of systemic ifxn + some purulence; IV abx - Ampicillin - Cloxacillin - Cefazolin - Clindamycin (penicillin allergy) 3. severe = signs of systemic ifxn/failed oral therapy/immunocompromised; broader coverage + possibility of necrotizing fasciitis IV - Pip-tazo - Cefepime (4th gen) - Meropenem if MRSA risk factors - Vanco, daptomycin, linezolid
32
Describe the treatment to be given for non-purulent SSTI in a patient with a history of water exposure
+ Cipro to cover Aeromonas, Vibrio & Pseudomonas
33
What is the typical duration of treatment for nonpurulent SSTIs?
5-10 days 14 days for immunocompromised
34
What are some other things to do when treating nonpurulent SSTIs?
1. rest 2. limb elevation to promote drainage of edema 3. treat underlying conditions (eg. tinea pedis, skin dryness, limb edema)
35
What are the monitoring parameters when monitoring for therapeutic response of SSTI treatment?
- improvement within 2-3 days (won't resolve so fast) - no progression of lesions/development of complications - reassess indication/choice of abx if no improvement within 2-3 days
36
How do DFIs (diabetic foot infections) come about? (Pathogenesis)
1. risk factors - neuropathy (loss of sensation) - vasculopathy (poor circulation) - immunopathy 2. ulcer formation/wound 3. bacterial colonize, penetration, proliferation 4. DFIs
37
What constitutes DFIs?
- wounds - ulcers
38
When do we treat wounds and ulcers found in diabetic patients?
if infected (ie. true DFI) criteria for infection: 1. purulent discharge, or 2. at least 2 signs of inflammation - erythema - warmness - tender - pain - induration (thickening/hardening of skin)
39
What are the microbes involved in DFIs?
typically polymicrobial G(+) - Staph, Strep G(-) (for wet/chronic wounds) - Proteus, Klebsiella, E Coli Anaerobes (for deep/ischemic/necrotic wounds) - Peptostreptococcus (Finegolda magna in SOA table) - Veillonella - Bacteroides
40
When and how do we take cultures for DFIs?
no need for mild DFI need for moderate to severe DFI take deep tissue cultures after cleansing + before starting empiric abx - avoid skin swabs - do not culture uninfected wounds
41
What is the criteria for mild DFI?
- involves skin + SQ tissue, AND - erythema ≤2cm, AND - no signs of systemic infection
42
What are the organisms to cover for mild DFI?
- Staph aureus - Strep species
43
What are the antibiotics to use for mild DFI?
PO abx - Cloxacillin - Cephalexin - Clindamycin if MRSA risk factors (PO) - Co-trimoxazole - Doxycyline - Clindamycin
44
What is the criteria for moderate DFI?
- involves deeper tissues (eg. bones, joints), OR - erythema >2cm - no signs of systemic infection (compulsory)
45
What are the organisms to cover for moderate DFI?
G(+) - Staph - Strep G(-) - +/- PA anaerobes
46
What are the antibiotics to use for moderate DFI?
IV abx - Amox/clav (Augmentin) - Cefazolin/Ceftriaxone + Metronidazole if MRSA risk factors (IV) - Vanco - Daptomycin - Linezolid
47
What is the criteria for severe DFI?
- involves deeper tissues (eg. bones, joints) OR - erythema >2cm - signs of systemic infection (compulsory)
48
What are the organisms to cover for severe DFI?
G(+) - Staph, strep G(-) - PA anaerobes
49
What are the antibiotics to use for severe DFI?
IV abx - Pip-tazo - Cefepime + metronidazole - Meropenem - Cipro + clindamycin if MRSA risk factors (IV) - Vanco - Daptomycin - Linezolid
50
What is the recommended duration of therapy for DFIs 1. not involving bones (mild, moderate, severe) 2. involving bones A: surgery - infected tissue completely removed, residual infected tissue left, residual viable bone left B: no surgery
Not involving bones * mild: 1-2 wks * moderate: 1-3 wks * severe: 2-4 wks Involving bone * surgery, complete removal: 2-5 days * surgery, residual infected tissue: 1-3 wks * surgery, residual viable bone: 4-6 wks * no surgery: ≥3 months
51
What are some adjunctive measures for DFIs?
* wound care * foot care * glycemic control
52
What are some risk factors for pressure ulcers?
1. reduced mobility 2. impaired immunity
53
When do we treat pressure ulcers with antibiotics?
when it becomes infected, meaning 1. purulent discharge 2. ≥2 signs of inflammation (erythema, warmness, tender, pain, induration)
54
What are some adjunctive measures for pressure ulcers?
1. debridement of infected/necrotic tissue 2. local wound care 3. relief pressure